title: 1999: a time to re-evaluate AIDS vaccine strategies.
abstract: The field of AIDS vaccine development is in flux. Important new findings were reported in 1999 that led to a rethinking of AIDS vaccine strategies. We have been given the challenging task of providing an overview. Rather than attempting to provide a comprehensive summary, we will restrict our discussion to a few major topics, and we ask for understanding if we can only highlight.
authors.affiliation: Dana-Farber Cancer Institute and Harvard Medical School, Boston, Massachusetts 02115, USA. ruth_ruprecht@dfci.harvard.edu
authors.forename: R M
authors.initials: RM
authors.lastname: Ruprecht
authors.forename: R
authors.initials: R
authors.lastname: Hofmann-Lehmann
authors.forename: R A
authors.initials: RA
authors.lastname: Rasmussen
authors.forename: J
authors.initials: J
authors.lastname: Vlasak
authors.forename: W
authors.initials: W
authors.lastname: Xu
mesh_terms: D016915:AIDS Vaccines / Q000096:biosynthesis; D000163:Acquired Immunodeficiency Syndrome / Q000517:prevention & control* / Q000821:virology; D000818:Animals; D000906:Antibodies / Q000627:therapeutic use; D001667:Binding, Competitive; D017353:Gene Deletion; D015754:Genes, nef / Q000235:genetics / Q000276:immunology; D006678:HIV / Q000235:genetics / Q000276:immunology; D006801:Humans; D009500:Neutralization Tests; D015302:Simian Immunodeficiency Virus / Q000235:genetics / Q000276:immunology; D014613:Vaccines, Attenuated / Q000096:biosynthesis
chemical_list: D016915:AIDS Vaccines; D000906:Antibodies; D014613:Vaccines, Attenuated